1. Home
  2. LEGH vs OMER Comparison

LEGH vs OMER Comparison

Compare LEGH & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Legacy Housing Corporation (TX)

LEGH

Legacy Housing Corporation (TX)

N/A

Current Price

$20.55

Market Cap

495.0M

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$8.82

Market Cap

628.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LEGH
OMER
Founded
2005
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
495.0M
628.9M
IPO Year
2018
2009

Fundamental Metrics

Financial Performance
Metric
LEGH
OMER
Price
$20.55
$8.82
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$25.00
$27.50
AVG Volume (30 Days)
126.6K
1.5M
Earning Date
11-07-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.95
N/A
Revenue
$180,497,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.07
N/A
P/E Ratio
$10.47
N/A
Revenue Growth
10.25
N/A
52 Week Low
$18.84
$2.95
52 Week High
$29.45
$13.60

Technical Indicators

Market Signals
Indicator
LEGH
OMER
Relative Strength Index (RSI) 48.95 46.20
Support Level $20.08 $8.27
Resistance Level $20.87 $11.71
Average True Range (ATR) 0.62 0.72
MACD 0.21 -0.31
Stochastic Oscillator 73.33 17.04

Price Performance

Historical Comparison
LEGH
OMER

About LEGH Legacy Housing Corporation (TX)

Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: